Scarica l'app Stockscreener
1.55
6.16%
0.09
Dopo l'orario di chiusura:
1.54
-0.01
-0.65%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ALZN Giù?
Forum
Previsione
Frazionamento azionario
Alzamend Neuro Inc Borsa (ALZN) Ultime notizie
Alzamend Neuro (ALZN) Drops 3.5% to $1.38 as Shares Approach Key SupportBreak of Structure - dars.gov.et
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending - marketscreener.com
Alzamend Neuro secures $7.5M in initial funding tranche - Investing.com
Alzamend Neuro Secures $25 Million Preferred Stock Financing - TipRanks
Alzamend Neuro Secures Up to $25 Million Series D Preferred Financing; $7.5 Million Funded - TradingView
Alzamend Neuro Received Notice of Noncompliance - TradingView
Alzamend Neuro’s New Lithium Study Puts AL001 in the Bipolar Disorder Spotlight - TipRanks
ALZN|Alzamend Neuro Inc|Price:1.350|Chg%:+0.040 - TradingKey
Alzamend Neuro Inc reports results for the quarter ended April 30Earnings Summary - TradingView
TradingKey - TradingKey
Alzamend Neuro Inc (ALZN) Cash Flow - TradingKey
Alzamend Neuro Inc (ALZN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alzamend Neuro, Inc. Revenue Breakdown – NASDAQ:ALZN - TradingView
Alzamend Neuro Inc (ALZN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alzamend Neuro Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Alzamend Neuro Announces Passing of Board Director - The Globe and Mail
Alzamend Neuro FY 2026: Revenue $0 EPS $(2.63) — 10-K Summary - TradingView
ALZN Q2 2026 Earnings: EPS Beat of 70.46% Surprise, No Revenue Reported, Stock Rises 1.52%EPS Consistency Score - dars.gov.et
Alzamend Neuro Announces Passing of Director Fahey McGrath, Ph.D. in July 2026 – SEC 8-K Filing Details 7 - Minichart
ALZN Q2 2026 Earnings: EPS Surpasses Estimates by Wide Margin Amidst Pre-Revenue StageFiscal Year Earnings - dars.gov.et
Price to sales forward of Alzamend Neuro, Inc. – BOATS:ALZN - TradingView
ALZN Q2 2026 Earnings: Narrower-than-expected loss sparks positive market reactionFiscal Year Earnings - dars.gov.et
ALZN Q2 2026 Earnings: EPS Beat by 70% but No Revenue – Stock Jumps on SurpriseGuidance Upgrade Report - dars.gov.et
$Alzamend Neuro (ALZN.US)$ it be like that - Moomoo
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
ALZN Q4'25 Earnings: EPS estimate is (0.67) USD - TradingView
Alzamend Neuro | DEF 14A: Definitive information statements - Moomoo
Alzamend Neuro, Inc. Actuals & Estimates (NASDAQ:ALZN) - TradingView
Alzamend Neuro, Inc. Actuals & Estimates (BOATS:ALZN) - TradingView
Price to book forward of Alzamend Neuro, Inc. – NASDAQ:ALZN - TradingView
ALZN Forecast — Price Target — Prediction for 2027 - TradingView
Alzamend Neuro (ALZN) Slips 3.1% as Stock Tests Key Support at $1.19Rounding Bottom - DonanımHaber
Enterprise value to revenue forward of Alzamend Neuro, Inc. – NASDAQ:ALZN - TradingView
Price to sales forward of Alzamend Neuro, Inc. – NASDAQ:ALZN - TradingView
ALZN Q4'25 Earnings: revenue estimate is 0 USD - TradingView
ALZN Q1 2026 Earnings: Narrower-Than-Expected Loss SurprisesFiscal Year Earnings - dars.gov.et
Alzamend Neuro (ALZN) Faces Modest Pressure Amid Broader Biotech UncertaintyPrice Target - dars.gov.et
Alzamend Neuro Inc (ALZN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alzamend Neuro Inc (ALZN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alzamend Neuro Inc (ALZN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alzamend Neuro Inc (ALZN) Institutional Confidence - TradingKey
Alzamend Neuro (ALZN) Edges Lower, Tests Support Levels Amid Biotech Sector VolatilityNHNL Ratio - dars.gov.et
Alzamend Neuro Inc (ALZN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alzamend Neuro Inc (ALZN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ALZN Q1 2026 Earnings: Smaller-than-Expected Loss Drives Shares HigherEarnings Manipulation Risk - newsline.com
Alzamend Neuro, Inc. Financial Disclosures & SEC Filings - TradingView
Alzamend Neuro (ALZN) Proxy filing Summary - Quartr
ALZN Q1 2026 Earnings: Narrower-than-Expected Loss Delivers 70% Positive SurpriseEarnings Revision Downgrade - newsline.com
Alzamend Neuro Shares Dip With AL001 Trial in Focus, Cash Concerns Linger - Bez Kabli
ALZN Q1 2026 Earnings: Significant EPS Beat Driven by Narrower-than-Expected LossOne-Time Loss Impact - newsline.com
Alzamend Neuro, Inc.Common Stock (NQ: ALZN - FinancialContent
Alzamend Neuro (ALZN) Gains 3.48% as Positive Momentum BuildsWave Equality - dars.gov.et
ALZN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Management Amid Pre-Revenue PhaseSaaS Earnings Trends - The Legal Advocate
Alzamend Neuro Inc. (ALZN) Stalls Near Support: Consolidation or Caution for This Alzheimer’s Play?Momentum Factor - thelegaladvocate.com
Alzamend Neuro (ALZN) Slides 1.74% as Stock Tests Key Support at $1.07Overvalued Signals - dars.gov.et
ALZNAlzamend Neuro Inc Stock Price and Quote - Finviz
Alzamend Neuro Inc. (ALZN) Q1 2026 Earnings: Narrower-than-Expected Loss as Early-Stage Biotech Continues R&D FocusEarnings Quality Score - newsline.com
ALZN Q1 2026 Earnings: Narrowing Losses Beat Estimates by 70%EBITDA Estimate Trend - newsline.com
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):